Stockreport

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals [Yahoo! Finance]

Aerovate Therapeutics, Inc.  (AVTE) 
PDF from the mid-stage portion of the IIb/III IMPAHCT study evaluating its lead candidate, AV-101, in adults with pulmonary arterial hypertension (PAH). The mid to late-st [Read more]